Heparesc

Promethera Announces Review Acceptance of Heparesc New Drug Submission for Neonatal Onset Urea Cycle Disorders by Health Canada

Mont-Saint-Guibert, Belgium, July 3, 2017 – Promethera Biosciences SA, a global innovator in cell-based medicines, today announced that Health Canada has accepted its New Drug Submission (NDS) of Heparesc in neonatal onset Urea Cycle Disorders (UCD) for review. UCDs are ultra-rare genetic disorders causing the accumulation of toxic ammonia levels for which liver transplantation is currently the only curative, but not immediately available, treatment to correct the metabolic defects.